OBI Pharma Receives ‘Most Promising ADC Clinical Candidate in Taiwan’ Award
Dr. Heidi Wang Accepts Award on Behalf of OBI Pharma at ADC Asia Congress 2025 and Gives a Presentation

At the ADC Asia Congress 2025 held today (3/12) in Singapore, OBI Pharma (4174.TWO) was honored with the "Most Promising ADC Clinical Candidate in Taiwan" award. This recognition follows OBI Pharma’s achievement last year as a candidate in the World ADC Awards, where it was shortlisted among the top eight international pharmaceutical companies. The award further underscores the industry's acknowledgment of OBI Pharma’s expertise in developing ADC (antibody-drug conjugate) therapeutics.